MedPath

Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery

Phase 4
Completed
Conditions
Uterine Fibroids
Fertility Disorders
Interventions
Other: Ringer lactate solution
Device: Prevadh film
Registration Number
NCT01388907
Lead Sponsor
Medtronic - MITG
Brief Summary

The purpose of this study was to evaluate clinically the efficacy of the PREVADH® Film in the prevention of adhesions in gynaecologic surgery, and to assess post-operative complications related to adhesions and pregnancy rate after myomectomy by open surgery.

Detailed Description

This study was addressed to patients having an immediate or differed pregnancy desire and presenting a symptomatic or asymptomatic fibroma being able to interfere with fertility.

* The primary end point was the assessment of adhesion rate to the uterine surgical sites during a laparoscopic second look performed 10 to 20 weeks post-surgery.

* The secondary end points were the assessment, throughout a 3 years follow-up period, of:

* pregnancy rate,

* adverse events related to adhesions,

* adnexal adhesions according to American Fertility Society score,

* abdomino-pelvic adhesions according to the modified American Fertility Society score.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
61
Inclusion Criteria
  • Symptomatic(s) or asymptomatic(s) uterin(s) fibroma(s) being able to interfere with the fertility by the patient who having an immediate or differed desire of pregnancy.
  • Size: diameter ≥ 6 cm at echographia (for the highest diameter)
  • Location interstitial and / or subserosa
  • planned laparotomic surgery
  • negative pregnancy test within 48 hours of surgery
  • signed inform consent
Exclusion Criteria
  • History of abdomino-pelvic surgery (except appendicectomy - cesarotomy)
  • Pre-operative embolization
  • Endometriosis stage >1 (American Fertility Society classification ≥ 5)
  • Pregnant patient
  • Diabetes
  • Chronic corticotherapy / immuno-supressor or immuno-modulator drugs
  • Previous analog LH-RH drug therapy for the uterine myoma

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ringer solutionRinger lactate solutionPatients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
Prevadh filmPrevadh filmPatient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
Primary Outcome Measures
NameTimeMethod
Number of Patients With Adhesions to Uterine Scars10 to 20 weeks post surgery

The primary endpoint was the assessment of adhesions to uterine scars and comprised the incidence (expressed per patient and per uterine scar), extent, and severity of adhesions observed during the second-look laparoscopy performed 10 to 20 weeks after the myomectomy.

This assessment was made by the surgeon (investigator) on the one hand and by two independent surgeons who reviewed the video recordings on the other hand.

Secondary Outcome Measures
NameTimeMethod
Fertility3 years

Fertility was assessed by pregnancy and deliveries rates at 3 years.

mAFS Abdominopelvic Adhesion Score10 to 20 weeks post surgery

mAFS abdominopelvic adhesion score in 23 sites (at the anterior caudal peritoneum; parietocolic gutter right; right and left colon; right and left anterior cranial peritoneum; rectosigmoid; omentum; small intestine; anterior and posterior uterus; posterior cul-de-sac; right and left ovaries \[internal and lateral sides\], pelvic side walls, ovarian fossae, tubes, and bulbs). It ranges from 0 (best possible outcome) to 16 (worse possible outcome).

Adnexal Adhesions10 to 20 weeks post surgery

Adnexal Adhesions were assessed by AFS score. AFS (= American Fertility Society) score was developed in 1980's by the American Fertility Society in an effort to address needs for a classification scheme for adnexal adhesions suspected to be associated with infertility. 4 anatomic sites evaluated: R-tube; R-ovary; L-tube; L-ovary. Final AFS score for a patient is the score of the side with lower summed score. The higher score, representing the side with the higher adhesion burden, is dropped; Score AFS is from 0 (best possible outcome) to 32 (worse possible outcome).

Trial Locations

Locations (11)

University Hospital

🇫🇷

Angers, France

UNIVERSITY HOSPITAL Estaing

🇫🇷

Clermont-ferrand, France

University Carémeau Hospital

🇫🇷

Nimes, France

Clinique du Tondu

🇫🇷

Bordeaux, France

Centre Hospitalier des quatre villes

🇫🇷

Sevres, France

Versailles Hospital

🇫🇷

Versailles, France

South University Hospital

🇫🇷

Rennes, France

Bichat Hospital - Claude Bernard (Public Assistance of Paris Hospital)

🇫🇷

Paris, France

TROUSSEAU Hospital (Public Assistance of Paris Hospital)

🇫🇷

Paris, France

Béclère Hospital (Public Assistance of Paris Hospital)

🇫🇷

Clamart, France

TENON Hospital (Public Assistance of Paris Hospital)

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath